The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...

Patients received 35 cycles of intravenous atezolizumab and obinutuzumab, a CD20-targeting monoclonal ... with 25% having received a BTK inhibitor only, 32% chemoimmunotherapy, and the rest ...

The company also has other products in its portfolio, including Umbralisib, an oral inhibitor for certain lymphomas ... a newly FDA-approved anti-CD20 monoclonal antibody, targets specific ...

Susac syndrome is a rare inflammatory vascular endotheliopathy affecting the small vessels of the brain, eye, and ear.1,2 ...

Richter transformation describes the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia, ...

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

One rival to Imjudo/Imfinzi in previously untreated HCC is Roche's dual regimen of PD-L1 inhibitor Tecentriq (atezolizumab) and CD20-targeting antibody Avastin (bevacizumab), which was approved by ...

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.